Shares of ProMIS Neurosciences, Inc. (TSE:PMN – Get Free Report) were down 3.8% on Monday . The company traded as low as C$5.98 and last traded at C$6.00. Approximately 19,701 shares traded hands during trading, an increase of 492% from the average daily volume of 3,327 shares. The stock had previously closed at C$6.24.
ProMIS Neurosciences Price Performance
The firm has a market cap of C$51.48 million, a price-to-earnings ratio of -1.78 and a beta of 1.19. The company has a current ratio of 0.51, a quick ratio of 1.30 and a debt-to-equity ratio of 108.33. The firm’s fifty day simple moving average is C$6.00.
ProMIS Neurosciences Company Profile
ProMIS Neurosciences, Inc discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.
Featured Articles
- Five stocks we like better than ProMIS Neurosciences
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- High-Yield Texas Instruments Could Hit New Highs Soon
- High Flyers: 3 Natural Gas Stocks for March 2022
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- Learn Technical Analysis Skills to Master the Stock Market
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for ProMIS Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMIS Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
